EXPERIENCE WITH INTRAPERITONEAL CHEMOTHERAPY USING ASCITIC FLUID AS A SOLVENT OF CHEMICALS IN THE TREATMENT OF OVARIAN CANCER
Thirty two with the ascitic form of Stages IIIC-IV ovarian cancer underwent 1 to 3 courses of intraperitoneal multidrug therapy using a protein ascitic fluid concentrate (PAFC) as a solvent of drugs (cisplatin, cyclophosphan, doxorubicin) according to the CAP regimen. The induction chemotherapy allo...
Saved in:
Main Authors: | Yu. S. Sidorenko (Author), G. A. Nerodo (Author), A. P. Menshenina (Author), L. Yu. Golotina (Author), N. D. Ushakova (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2014-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of hyperthermic intraperitoneal chemotherapy in combination with an intraperitoneal port system in the treatment of patients with advanced ovarian cancer
by: V. V. Saevets, et al.
Published: (2022) -
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
by: Maurie Markman
Published: (2009) -
The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
by: Kate Glennon, et al.
Published: (2021) -
Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
by: Jieun Ko, et al.
Published: (2021) -
Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer
by: Laura M. Chambers, et al.
Published: (2022)